FindTrial
Sign In

Observational study of different dosages of ATG-F used in conditioning of HLA haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion

Observational study of different dosages of ATG-F used in conditioning of HLA haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OND-16009502
Enrollment
Unknown
Registered
2016-10-20
Start date
2016-10-20
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematologic malignancy

Interventions

A:ATG-F 5mg/kg*2d
B:ATG-F 5mg/kg*4d

Sponsors

The Second Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Aged 15-60y; 2. hematological malignancies; 3. prepared for related haploidentical HSCT; 4. signed consent form.

Exclusion criteria

Exclusion criteria: 1. Allergic to ATG-F; 2. unconsented.

Design outcomes

Primary

MeasureTime frame
GVHD;the relapse of leukemia post-transplantation;2-years OS post-transplantation;2-years DFS post-tansplantation;—

Countries

China

Contacts

Public ContactYun Luo

The Second Affiliated Hospital of Chongqing Medical University

luo555@163.com+86 13452393932

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026